Sen-Jam Pharmaceutical
Own a stake for health equality; affordable and accessible for all
Overview
Raised: $1,008,951
Total Commitments ($USD)
Wefunder
12/02/2021
07/31/2022
$100
Convertible Note
Pre-Seed
RegCF
$20,000,000
$25,000,000
20%
Rolling Commitments ($USD)
07/31/2022
$4,187
386
2017
Healthcare & Pharmaceuticals
Biotech
B2B
High
High
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$860 |
| ||
| ||
|
Net Income |
$-368,918 |
$-280,006 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$12,240 |
$174 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$634,559 |
$670,364 |
|
Short-Term Debt |
$22,039 |
$0 |
|
Long-Term Debt |
$395,075 |
$0 |
|
Total Liabilities |
$417,114 |
$0 |
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Sen-Jam Pharmaceutical | 04/29/2024 | Wefunder | $80,000,000 | $902,184 | Convertible Note | Active | RegCF / RegD 506(c) |
| Sen-Jam Pharmaceutical | 04/25/2024 | Dealmaker Securities | - | - | Convertible Note | Active | RegD 506(c) |
| Sen-Jam Pharmaceutical | 01/11/2023 | StartEngine | $69,979,019 | $312,093 | Equity - Common | Funded | RegCF |
| Sen-Jam Pharmaceutical | 07/31/2022 | Wefunder | $25,000,000 | $1,008,951 | Convertible Note | Funded | RegCF |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Founder Profile
Sen-Jam Pharmaceutical Founder Jim Iversen on Making Effective and Affordable Drugs
Prescription drug prices in the United States are painfully high. Americans pay more than twice as much as other countries for medication. This can weigh especially heavily on individuals without insurance who are struggling to make ends meet.In recognition of this problem, Sen-Jam Pharmaceutical aims to develop and sell affordable and effective oral anti-inflammation medicine. The company is working on eight products to address specific conditions, including COVID-19, opioid withdrawal, and hangovers. We reached out to co-founder and CEO Jim Iversen to learn more about the origins of the business and its plans following the raise.
Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.